Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840088 | 0.94 | CACNA1B (0.53) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL4844846 | 0.93 | CACNA1B (0.56) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL4844481 | 0.93 | CACNA1B (0.46) | CACNA1BALDH1A1CTSSCPB2CTSL | |
| SCHEMBL4843189 | 0.92 | CACNA1B (0.56) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL5361323 | 0.92 | CACNA1B (0.61) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL4842875 | 0.91 | CACNA1B (0.55) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL4845009 | 0.91 | CACNA1B (0.55) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL4843256 | 0.90 | CACNA1B (0.57) | CACNA1BALDH1A1HRH3TACR1MAPK14 | |
| SCHEMBL4841915 | 0.88 | CACNA1B (0.59) | CACNA1BALDH1A1HRH3TACR1BCL2 | |
| SCHEMBL4836043 | 0.87 | CACNA1B (0.51) | CACNA1BALDH1A1HRH3TACR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | claimed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | claimed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-6903119-B1 | Amino acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1B, CACNA1A | CACNA1B 2/4885ALDH1A1 3828/4885HRH3 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.